Le Lézard
Classified in: Health
Subjects: NPT, SVY

JOMS study: Oral biopsies provide opportunity to discuss oral cancer risk factors

ROSEMONT, Ill., Oct. 6, 2017 /PRNewswire-USNewswire/ -- A new study suggests a doctor-patient discussion of risk factors at the time of oral cancer biopsies could be "an important initial step" toward behavior changes of at-risk patients.

The experts in face, mouth and jaw surgery(TM) - The American Association of Oral and Maxillofacial Surgeons (AAOMS), the professional organization representing more than 9,500 oral and maxillofacial surgeons in the United States, supports its fellows' and members' ability to practice their specialty through education, research and advocacy. AAOMS fellows and members comply with rigorous continuing education requirements and submit to periodic office anesthesia evaluations. Visit MyOMS.org for additional information about oral and facial surgery.

The study, published in the October issue of the Journal of Oral and Maxillofacial Surgery, encourages doctors to advise their oral cancer biopsy patients of the risk factors associated with continued tobacco and alcohol use.

"Knowledge of the relation between oral biopsy and behavior change can be very important for oral and maxillofacial surgeons and other clinicians who deliver diagnoses and arrange for disease treatment because these providers are in a unique position to influence at-risk patients and lower the overall use of the chief etiologic agents responsible for oral cancer," the authors said.

The study, published in the official journal of the American Association of Oral and Maxillofacial Surgeons, looked at the behavior changes of 605 patients to determine the association between changes in alcohol or tobacco use and an oral biopsy (an examination of cells or tissues removed from a body to check for the presence of a disease). Adults diagnosed with hyperkeratosis (a thickening of the skin's outer layer), dysplasia (abnormal precancerous tissue), or carcinoma (a type of cancer) were included in the study. 

Larger percentages of patients with more severe clinical diagnoses quit smoking and stopped drinking alcohol following their biopsies, the study found. A higher percentage of patients with dysplasia quit than those with hyperkeratosis, a promising finding because dysplasia has shown to be potentially reversible, researchers wrote.

Nearly 36 percent of tobacco users at the time of their biopsy quit smoking after the exam, and almost 9 percent who were using alcohol stopped drinking after undergoing a biopsy.

Age and race were connected to behavior changes, emphasizing "the need for clinicians to address cessation with all types of patients," the researchers concluded. The youngest respondents ? ages 21 to 52 ? were 3.7 times more likely to continue to smoke before or after a biopsy. White non-Hispanics were less likely to quit drinking alcohol before and after biopsy than other races.

During diagnosis, doctors can provide "objective, personal and tangible evidence of physical harm resulting from" tobacco and alcohol use to potentially change patient behavior, researchers wrote.

"Informing a patient that surgical removal of a suspicious lesion is recommended enlightens the patient to the fact that the patient's health could be in jeopardy and that a painful procedure is recommended to determine this possibility," authors wrote. "Also, delivery of the biopsy diagnosis serves as an opportunity to highlight unequivocally how the patient's tissues are being affected and how cessation would be directly beneficial."

The authors of "Is Oral Biopsy Associated With Change in Tobacco or Alcohol Use?" ? all from the University of North Carolina in Chapel Hill, N.C. ? are: Tiffany M. Peters, DDS, MS, Adjunct Assistant Professor, Department of Diagnostic Sciences; Ceib Phillips, PhD, MPH, Assistant Dean for Graduate/Advanced Education, Department of Orthodontics; and Valerie A. Murrah, DMD, MS, Professor and Chair, Department of Diagnostic Sciences; Director, Division of Oral and Maxillofacial Pathology.

The full article can be accessed at www.joms.org/article/S0278-2391(17)30337-3/fulltext.

The Journal of Oral and Maxillofacial Surgery is published by the American Association of Oral and Maxillofacial Surgeons to present to the dental and medical communities comprehensive coverage of new techniques, important developments and innovative ideas in oral and maxillofacial surgery. Practice-applicable articles help develop the methods used to handle dentoalveolar surgery, facial injuries and deformities, TMJ disorders, oral and head and neck cancer, jaw reconstruction, anesthesia and analgesia. The journal also includes specifics on new instruments and diagnostic equipment, and modern therapeutic drugs and devices.

CONTACT: Jolene Kremer, Associate Executive Director, Communications & Publications,
American Association of Oral and Maxillofacial Surgeons
Phone: 847-233-4336
Fax: 847-678-6286

SOURCE American Association of Oral & Maxillofacial Surgeons

These press releases may also interest you

at 17:00
CryoLife, Inc. , a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Deutsche Bank 26th Annual Leveraged Finance Conference on Tuesday, October 2, 2018 at The Phoenician...

at 16:49
Leading researchers in emergency medicine will present nearly 500 studies during the Research Forum at ACEP18-Scientific Assembly, the annual meeting of the American College of Emergency Physicians (ACEP) at the San Diego Convention Center from...

at 16:35
The safety of the American food supply is one of the U.S. Food and Drug Administration's highest priorities. A key part of our work in this space focuses on implementing the principles and measures of the FDA Food Safety Modernization Act (FSMA). The...

at 16:33
Profound Medical Corp. ("Profound" or the "Company"), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance ("MR") imaging combined with the safety and ablation power of directional and...

at 16:30
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of erdafitinib for the treatment of patients with locally...

at 16:15
Aflac Incorporated announced today that it will webcast its annual Financial Analysts Briefing on September 25, 2018 at 7:00 p.m. (ET), which will be held on September 26, 2018 at 8:00 a.m. (JST) in Tokyo. Aflac's management will discuss its...

News published on 6 october 2017 at 02:30 and distributed by: